论文部分内容阅读
目的:探讨E6-AP3种转录本在宫颈癌的表达及其临床意义。方法:免疫组织化学SP法检测30例宫颈癌组织及20例正常宫颈组织中E6-AP蛋白的表达,分析E6-AP的表达与宫颈癌病理分级之间的关系。同时用W estern blot检测E6-AP在正常宫颈脱落细胞和宫颈癌脱落细胞的表达水平。RT-PCR方法明确E6-AP 3种转录本在正常宫颈组织和宫颈癌组织中的表达。结果:RT-PCR结果显示E6-AP3种亚型在宫颈癌组织中均存在,并且表达高于正常子宫颈组织,其中Ⅱ型表达水平很低,以Ⅰ型和Ⅲ型为主。免疫组化和W estern B lot结果显示E6-AP在宫颈癌组织表达水平高于正常宫颈组织。结论:E6-AP表达升高可能与宫颈癌的发病机制相关。
Objective: To investigate the expression of E6-AP3 transcript in cervical cancer and its clinical significance. Methods: Immunohistochemical SP method was used to detect the expression of E6-AP protein in 30 cases of cervical cancer and 20 cases of normal cervical tissue. The relationship between E6-AP expression and pathological grade of cervical cancer was analyzed. Meanwhile, the expression of E6-AP in normal cervical exfoliated cells and cervical exfoliated cells was detected by Western blot. The expression of E6-AP 3 transcripts in normal cervical tissues and cervical cancer tissues was determined by RT-PCR. Results: The results of RT-PCR showed that E6-AP3 subtypes existed in cervical cancer tissues and their expression was higher than that in normal cervical tissues. The expression level of type Ⅱ was very low, mainly type Ⅰ and Ⅲ. Immunohistochemistry and Western B lot results showed that E6-AP expression in cervical cancer tissue levels higher than normal cervical tissue. Conclusion: The increased expression of E6-AP may be related to the pathogenesis of cervical cancer.